AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19863538 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy alone
Number of subjects: 161
Study 19863538 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD detected prior to autologous stem cell transplantation (SCT)
Number of subjects: 161
Study 19863538 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic-SCT in first complete remission with MRD positivity pre-transplant
Number of subjects: 161
Study 18548293 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified condylotomy
Number of subjects: 8
Study 18548293 — intervention group
Group type: COMPARATOR
Intervention: Conventional nonsurgical treatment
Number of subjects: 8
Study 16639486 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 151
Study 16639486 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 151
Study 16639486 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Etanercept and Infliximab
Number of subjects: 151
Study 15370078 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Arginine (L-Arg 20 g/500 ml)
Number of subjects: 15
Study 15370078 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline infusion)
Number of subjects: 15
Study 11080405 — intervention group
Group type: COMPARATOR
Intervention: ondansetron 4 mg IV
Number of subjects: 108
Study 11080405 — intervention group
Group type: EXPERIMENTAL
Intervention: dimenhydrinate 50 mg IV
Number of subjects: 108
Study 9396185 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis of treatments
Number of subjects: 0
Study 9396185 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative meta-analysis
Number of subjects: 0
Study 9396185 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis on individual patient data
Number of subjects: 0
Study 9396185 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-Based Medicine (EBM)
Number of subjects: 0
Study 9396185 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochrane Collaboration
Number of subjects: 0
Study 8294195 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine 1mg and metoclopramide 10mg IV
Number of subjects: 28
Study 8294195 — intervention group
Group type: COMPARATOR
Intervention: Meperidine 75mg and hydroxyzine 75mg IM
Number of subjects: 28
Study 3319459 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-ASA enemas
Number of subjects: 59
Study 3319459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 29436486 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine
Number of subjects: 13
Study 29436486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 26875922 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaw thrust (Group J)
Number of subjects: 100
Study 26875922 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapezius squeezing test (Group T)
Number of subjects: 100
Study 24704801 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐emptive methylprednisolone infusion (5 mg/kg) before radiotherapy (Group 1)
Number of subjects: 120
Study 24704801 — intervention group
Group type: COMPARATOR
Intervention: Short‐course radiotherapy without methylprednisolone infusion (Group 2)
Number of subjects: 120
Study 24704801 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐emptive methylprednisolone infusion (Group 1)
Number of subjects: 120
Study 22344753 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary specialist mental health consultation
Number of subjects: 44
Study 22344753 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 44
Study 20479348 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen sponge group
Number of subjects: 115
Study 20479348 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 115
Study 18589271 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioabsorbable interference screws
Number of subjects: 100
Study 18589271 — intervention group
Group type: COMPARATOR
Intervention: Titanium interference screws
Number of subjects: 100
Study 15869338 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirically supported treatments (ESTs)
Number of subjects: 0
Study 15869338 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized trial methodology
Number of subjects: 0
Study 15869338 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlational research designs proposed by Westen et al.
Number of subjects: 0
Study 12592686 — intervention group
Group type: EXPERIMENTAL
Intervention: Astragalus injection (20 ml in 250 ml of normal saline, once per day for 21 days, 4 courses)
Number of subjects: 120
Study 12592686 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (control group)
Number of subjects: 120
Study 10342509 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin-glycerin trinitrate combination (TER-GTN)
Number of subjects: 84
Study 10342509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 8564726 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (120 mg/die for 7 days)
Number of subjects: 20
Study 8564726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1720262 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose aprotinin (2 million KIU after induction of anesthesia followed by 500,000 KIU/h infusion throughout the operation)
Number of subjects: 50
Study 1720262 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aprotinin)
Number of subjects: 50
Study 1720262 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose aprotinin
Number of subjects: 50
Study 7045313 — intervention group
Group type: EXPERIMENTAL
Intervention: Vidarabine
Number of subjects: 34
Study 7045313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 31578631 — intervention group
Group type: EXPERIMENTAL
Intervention: Photoselective laser vaporisation of the prostate (PVP)
Number of subjects: 665
Study 31578631 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for postoperative UTIs
Number of subjects: 665
Study 31578631 — intervention group
Group type: COMPARATOR
Intervention: Antimicrobial prophylaxis
Number of subjects: 665
Study 31852355 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-grass-pollen-allergoid (Allergovit®) treatment initiated during pollen season (Group-A)
Number of subjects: 240
Study 31852355 — intervention group
Group type: COMPARATOR
Intervention: 6-grass-pollen-allergoid (Allergovit®) treatment initiated outside pollen season (Group-B)
Number of subjects: 240
Study 31852355 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 240
Study 28392271 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive high intensity power training, 2 sessions per week for 12 weeks
Number of subjects: 47
Study 28392271 — intervention group
Group type: COMPARATOR
Intervention: No interventions (control group)
Number of subjects: 47
Study 25495666 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy tablet (SLIT-tablet) MK-7243 (2800 BAU/75 000 SQ-T)
Number of subjects: 4195
Study 25495666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4195
Study 24911342 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue injection
Number of subjects: 100
Study 24911342 — intervention group
Group type: COMPARATOR
Intervention: Standard manual palpation technique
Number of subjects: 100
Study 22342469 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal danazol 400mg
Number of subjects: 91
Study 22342469 — intervention group
Group type: COMPARATOR
Intervention: Oral danazol 600mg
Number of subjects: 91
Study 20885182 — intervention group
Group type: EXPERIMENTAL
Intervention: Health information exchange between medical and ancillary care providers for 2 years using electronic health records and printouts.
Number of subjects: 254
Study 20885182 — intervention group
Group type: COMPARATOR
Intervention: Control group (no health information exchange).
Number of subjects: 254
Study 17074328 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 30
Study 17074328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 16222884 — intervention group
Group type: EXPERIMENTAL
Intervention: FGF 1 l/min
Number of subjects: 90
Study 16222884 — intervention group
Group type: EXPERIMENTAL
Intervention: FGF 2 l/min
Number of subjects: 90
Study 16222884 — intervention group
Group type: EXPERIMENTAL
Intervention: FGF 4 l/min
Number of subjects: 90
Study 12148830 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-automatic method to measure and quantify geometrical and topological properties of continuous vascular trees from fundus images.
Number of subjects: 20
Study 12148830 — intervention group
Group type: COMPARATOR
Intervention: Semi-automatic method applied to normotensive subjects.
Number of subjects: 20
Study 12148830 — intervention group
Group type: COMPARATOR
Intervention: Semi-automatic method applied to hypertensive subjects.
Number of subjects: 20
Study 10431937 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring intervention with additional phone calls and daily mailings during the holiday season
Number of subjects: 57
Study 10431937 — intervention group
Group type: COMPARATOR
Intervention: Standard weekly cognitive-behavioral treatment for obesity (comparison group)
Number of subjects: 57
Study 7589022 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyrone 2 g i.m.
Number of subjects: 293
Study 7589022 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyrone 2 g i.v.
Number of subjects: 293
Study 7589022 — intervention group
Group type: COMPARATOR
Intervention: Dipyrone 1 g i.m.
Number of subjects: 293
Study 7589022 — intervention group
Group type: COMPARATOR
Intervention: Dipyrone 1 g i.v.
Number of subjects: 293
Study 7589022 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium 75 mg i.m.
Number of subjects: 293
Study 7589022 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium 75 mg i.v.
Number of subjects: 293
Study 2405777 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation.MCNU (MR group) with 50-60 Gy irradiation and 2 mg/kg MCNU intravenously on the initial day and 6 weeks later.
Number of subjects: 19
Study 2405777 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation.MCNU.interferon-beta (IMR group) with 50-60 Gy irradiation and 2 x 10(6) IU/m2 interferon-beta intravenously for 5 serial days every eight weeks.
Number of subjects: 19
Study 2405777 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of MCNU and interferon-beta.
Number of subjects: 19
Study 6344295 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous prostaglandin E1 (PGE1)
Number of subjects: 8
Study 6344295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31492661 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased abdominal subcutaneous adipose tissue (ScAT) inflammatory gene expression
Number of subjects: 368
Study 31492661 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased systemic low-grade inflammation profile
Number of subjects: 368
Study 31492661 — intervention group
Group type: EXPERIMENTAL
Intervention: Distinct abdominal ScAT transcriptome profiles
Number of subjects: 368
Study 31492661 — intervention group
Group type: EXPERIMENTAL
Intervention: Upregulated genes related to extracellular remodeling
Number of subjects: 368
Study 31492661 — intervention group
Group type: EXPERIMENTAL
Intervention: Upregulated genes related to inflammation
Number of subjects: 368
Study 27723281 — intervention group
Group type: EXPERIMENTAL
Intervention: Tabalumab (BAFF-blocking IgG4 monoclonal antibody)
Number of subjects: 1760
Study 27723281 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy donors)
Number of subjects: 1760
Study 26718394 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) designed to reduce drinking to cope (DTC) and anxiety symptoms
Number of subjects: 218
Study 26718394 — intervention group
Group type: COMPARATOR
Intervention: Progressive Muscle Relaxation Training (PMRT) designed to reduce anxiety symptoms only
Number of subjects: 218
Study 25061952 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 long clinical day (12 hours)
Number of subjects: 146
Study 25061952 — intervention group
Group type: COMPARATOR
Intervention: 2 shorter clinical days (7-8 hours each)
Number of subjects: 146
Study 21688163 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Qigong (MQ) program for 10 weeks
Number of subjects: 81
Study 21688163 — intervention group
Group type: COMPARATOR
Intervention: Usual health care (Control)
Number of subjects: 81
Study 19357642 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (8 mg per day)
Number of subjects: 46
Study 19357642 — intervention group
Group type: COMPARATOR
Intervention: Inhaled beclometasone dipropionate (200 microg per day)
Number of subjects: 46
Study 20335624 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10-20 mg/d for 4 to 15 months)
Number of subjects: 3869
Study 16270384 — intervention group
Group type: EXPERIMENTAL
Intervention: Purple sweet potato leaves (PSPL) diet (daily consumption of 200 g PSPL)
Number of subjects: 16
Study 16270384 — intervention group
Group type: COMPARATOR
Intervention: Control diet (low polyphenols, with the amount of carotenoids adjusted to the same level as that of PSPL)
Number of subjects: 16
Study 11875328 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (25-microg and 50-microg E(2) patch)
Number of subjects: 35
Study 11875328 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (100-microg E(2) patch)
Number of subjects: 35
Study 11875328 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (50-microg E(2) patch combined with P (300 mg/day) or MPA (5 mg/day))
Number of subjects: 35
Study 11875328 — intervention group
Group type: COMPARATOR
Intervention: Transdermal estradiol (E(2)) alone
Number of subjects: 35
Study 11875328 — intervention group
Group type: COMPARATOR
Intervention: Transdermal estradiol (E(2)) plus progestogen
Number of subjects: 35
Study 9661685 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic transfusion
Number of subjects: 84
Study 9661685 — intervention group
Group type: COMPARATOR
Intervention: Threshold transfusion
Number of subjects: 84
Study 8168297 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical surgery
Number of subjects: 112
Study 8168297 — intervention group
Group type: COMPARATOR
Intervention: Debridement surgery
Number of subjects: 112
Study 2964980 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (150 mg/day)
Number of subjects: 8
Study 29486338 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmitoylethanolamide (PEA) 600 mg twice daily
Number of subjects: 58
Study 29486338 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmitoylethanolamide (PEA)
Number of subjects: 58
Study 29486338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 27733252 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA 600mg/d
Number of subjects: 121
Study 27733252 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA 1800mg/d
Number of subjects: 121
Study 27733252 — intervention group
Group type: COMPARATOR
Intervention: EPA 600mg/d
Number of subjects: 121
Study 27733252 — intervention group
Group type: COMPARATOR
Intervention: Olive oil placebo 6g/d
Number of subjects: 121
Study 25568533 — intervention group
Group type: EXPERIMENTAL
Intervention: P. oleracea seeds (500 mg) taken two times a day for one month
Number of subjects: 0
Study 25568533 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose) capsules taken two times a day for one month
Number of subjects: 0
Study 22150754 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative ultrasound monitoring (scanned in ER and regularly at the ward until surgery)
Number of subjects: 281
Study 22150754 — intervention group
Group type: COMPARATOR
Intervention: No regular scanning before surgery (control group)
Number of subjects: 281
Study 22150754 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative ultrasound monitoring
Number of subjects: 281
Study 20510551 — intervention group
Group type: EXPERIMENTAL
Intervention: diacetylmorphine
Number of subjects: 226
Study 20510551 — intervention group
Group type: COMPARATOR
Intervention: oral methadone
Number of subjects: 226
Study 19041613 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Pain Inventory Short Form (BPI-SF)
Number of subjects: 106
Study 19041613 — intervention group
Group type: COMPARATOR
Intervention: Open-ended pain question
Number of subjects: 106
Study 16438017 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 10 mg diazepam in the evening before surgery and 1.5 mg midazolam at least 15 min before surgery
Number of subjects: 100
Study 16438017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 12592230 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg per day for 6 weeks)
Number of subjects: 19
Study 12592230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 10100957 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily plasmapheresis
Number of subjects: 30
Study 10100957 — intervention group
Group type: COMPARATOR
Intervention: Alternately daily plasmapheresis
Number of subjects: 30
Study 8671180 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 hour sperm-oocyte interaction (group 1)
Number of subjects: 119
Study 8671180 — intervention group
Group type: COMPARATOR
Intervention: 16 hours sperm-oocyte interaction (group 2)
Number of subjects: 119
Study 1671009 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (1 and 3 micrograms/dl forearm tissue/min)
Number of subjects: 0
Study 1671009 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (0.5 and 1 microgram/dl forearm tissue/min)
Number of subjects: 0
Study 6407518 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms levonorgestrel
Number of subjects: 0
Study 6407518 — intervention group
Group type: EXPERIMENTAL
Intervention: 350 micrograms norethisterone
Number of subjects: 0
Study 6407518 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30412450 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care professionals (physicians and psychotherapists)
Number of subjects: 1481
Study 30412450 — intervention group
Group type: COMPARATOR
Intervention: Nonprofessionals
Number of subjects: 1481
Study 29498948 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propofol
Number of subjects: 300
Study 29498948 — intervention group
Group type: COMPARATOR
Intervention: Inhalational sevoflurane
Number of subjects: 300
Study 26791869 — intervention group
Group type: EXPERIMENTAL
Intervention: ch14.18-UTC (17.5 mg/m²/day)
Number of subjects: 28
Study 26791869 — intervention group
Group type: COMPARATOR
Intervention: ch14.18-NCI (25 mg/m²/day)
Number of subjects: 28
Study 26791869 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ch14.18-UTC and ch14.18-NCI
Number of subjects: 28
Study 25170655 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero-profile device (ZPD) adjacent to a single-level ACDF
Number of subjects: 0
Study 25170655 — intervention group
Group type: COMPARATOR
Intervention: 2-level ACDF (C4-6)
Number of subjects: 0
Study 22710014 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-Initiated Problem Solving (TIPS) intervention
Number of subjects: 34
Study 22710014 — intervention group
Group type: COMPARATOR
Intervention: Wait-List Control group
Number of subjects: 34
Study 20564152 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 cycles of ABVD followed by irradiation at 36 Gy to initially involved sites and 24 Gy to adjacent sites, the upper infradiaphragmatic area, and the spleen.
Number of subjects: 390
Study 20564152 — intervention group
Group type: COMPARATOR
Intervention: 3 cycles of ABVD followed by irradiation at 40 Gy to initially involved sites and 30 Gy to adjacent sites, the upper infradiaphragmatic area, and the spleen.
Number of subjects: 390
Study 20564152 — intervention group
Group type: COMPARATOR
Intervention: Historic control group (HCG) receiving the same chemotherapy regimen and irradiation at doses of 40 Gy and 30 Gy, respectively.
Number of subjects: 390
Study 16499954 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous treatment with 2 mg 17beta‐estradiol plus 1 mg norethisterone acetate (n=30)
Number of subjects: 54
Study 16499954 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg raloxifene (n=24)
Number of subjects: 54
Study 16249712 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence intervention (2 clinics)
Number of subjects: 437
Study 16249712 — intervention group
Group type: COMPARATOR
Intervention: Safer sex intervention (4 clinics)
Number of subjects: 437
Study 16249712 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence intervention
Number of subjects: 437
Study 11260443 — intervention group
Group type: EXPERIMENTAL
Intervention: Observer role plays
Number of subjects: 160
Study 11260443 — intervention group
Group type: COMPARATOR
Intervention: Interpreter role plays
Number of subjects: 160
Study 9530972 — intervention group
Group type: EXPERIMENTAL
Intervention: Normosmic participants
Number of subjects: 35
Study 9530972 — intervention group
Group type: COMPARATOR
Intervention: Anosmic participants
Number of subjects: 35
Study 8028515 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (120 mg orally)
Number of subjects: 27
Study 8028515 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 tablets orally)
Number of subjects: 27
Study 2574930 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 46
Study 2574930 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 46
Study 1059202 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal concentric strength
Number of subjects: 40
Study 1059202 — intervention group
Group type: COMPARATOR
Intervention: Isometric contraction
Number of subjects: 40
Study 1059202 — intervention group
Group type: COMPARATOR
Intervention: Eccentric contraction
Number of subjects: 40
Study 31297658 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass hybrid restorative system (GH) (Equia Forte Fil, GC, Tokyo, Japan)
Number of subjects: 25
Study 31297658 — intervention group
Group type: COMPARATOR
Intervention: Nano-ceramic composite resin (RBC) (Ceram.X One Universal, Dentsply, DeTrey, Konstanz, Germany)
Number of subjects: 25
Study 30615896 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate prescription of glasses (1.00 D less than full cycloplegic hyperopia)
Number of subjects: 130